General Information of Drug Combination (ID: DCD287V)

Drug Combination Name
MK-1775 10-hydroxycamptothecin
Indication
Disease Entry Status REF
Carcinoma Investigative [1]
Component Drugs MK-1775   DM3WDZ5 10-hydroxycamptothecin   DM9WLN4
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: OV90
Zero Interaction Potency (ZIP) Score: 5.54
Bliss Independence Score: 7
Loewe Additivity Score: 0.5
LHighest Single Agent (HSA) Score: 10.35

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of MK-1775
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
MK-1775 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Wee1-like protein kinase (WEE1) TTJFOAL WEE1_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
MK-1775 Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Decreases Phosphorylation [5]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Response To Substance [5]
------------------------------------------------------------------------------------
Indication(s) of 10-hydroxycamptothecin
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [4]
10-hydroxycamptothecin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase I (TOP1) TTGTQHC TOP1_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
10-hydroxycamptothecin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [7]
------------------------------------------------------------------------------------
10-hydroxycamptothecin Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Response To Substance [8]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Affects Response To Substance [9]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Response To Substance [8]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DCYAV9W CAOV3 Investigative [10]
Adenocarcinoma DCKJVC3 A427 Investigative [10]
Adenocarcinoma DCJU6CE NCIH1650 Investigative [10]
Adenocarcinoma DCSFCWT NCIH2122 Investigative [10]
Adenocarcinoma DCT3STD NCIH23 Investigative [10]
Adenocarcinoma DCTACFW NCIH520 Investigative [10]
Adenocarcinoma DCFHGLW COLO320DM Investigative [10]
Adenocarcinoma DCE8N91 DLD1 Investigative [10]
Adenocarcinoma DCLYDCN HCT116 Investigative [10]
Adenocarcinoma DCNBFSS HT29 Investigative [10]
Adenocarcinoma DCMYNM0 SW-620 Investigative [10]
Amelanotic melanoma DCRBVT9 A2058 Investigative [10]
Ewing sarcoma-peripheral primitive neuroectodermal tumour DC7JN0B ES2 Investigative [10]
Germ cell tumour DCBUPKM PA1 Investigative [10]
Malignant melanoma DCXOCQE A375 Investigative [10]
Malignant melanoma DCOX20A HT144 Investigative [10]
Malignant melanoma DCUFHTV RPMI7951 Investigative [10]
Malignant melanoma DCL12RU SKMEL30 Investigative [10]
Malignant melanoma DC7WTA4 UACC62 Investigative [10]
Mesothelioma DC7F29S MSTO Investigative [10]
Non small cell carcinoma DCRANYM SKMES1 Investigative [10]
Ovarian endometrioid adenocarcinoma DCIPYX0 A2780 Investigative [10]
Ovarian serous cystadenocarcinoma DCE7JZD SK-OV-3 Investigative [10]
Prostate carcinoma DCS1873 LNCAP Investigative [10]
Prostate carcinoma DCW7VLR VCAP Investigative [10]
Breast and ovarian cancer syndrome DCAIH7B UWB1289+BRCA1 Investigative [1]
Breast carcinoma DCQITCE ZR751 Investigative [1]
Breast carcinoma DCR4NH7 KPL1 Investigative [1]
Breast carcinoma DCEVLLZ OCUBM Investigative [1]
Carcinoma DCLK4KW EFM192B Investigative [1]
Colon adenocarcinoma DCY5C8B LOVO Investigative [1]
Colon carcinoma DC0R11T RKO Investigative [1]
Invasive ductal carcinoma DCZOGE0 T-47D Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 33 DrugCom(s)

References

1 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7702).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways. Int J Oncol. 1998 Apr;12(4):793-804.
5 Functional kinomics identifies candidate therapeutic targets in head and neck cancer. Clin Cancer Res. 2014 Aug 15;20(16):4274-88. doi: 10.1158/1078-0432.CCR-13-2858.
6 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
7 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
8 siRNA-mediated Bcl-2 and Bcl-xl gene silencing sensitizes human hepatoblastoma cells to chemotherapeutic drugs. Clin Exp Pharmacol Physiol. 2007 May-Jun;34(5-6):450-6. doi: 10.1111/j.1440-1681.2007.04593.x.
9 Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11636-41. doi: 10.1073/pnas.1934692100. Epub 2003 Sep 16.
10 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.